Background. Polyunsaturated fatty acids (PUFA) are essential nutrients with anti-inflammatory and cardioprotective properties. We investigated the association of essential dietary PUFA intake, reflected by plasma fatty acid composition, with inflammation and mortality in dialysis patients. Methods. We recruited 222 Swedish dialysis subjects (39% women) with median age of 57 years and average 12 months of dialysis vintage. Plasma phospholipid PUFA were assessed by gas-liquid chromatography. Overall mortality was assessed after 18.4 (10th-90th percentiles: 2.3-60) months of follow-up. Results. Linoleic acid (LA), Mead acid (MA), α-linolenic acid (ALA) and long-chain n-3 PUFA (LC n-3; the sum of eicosapentaenoic, docosapentaenoic and docosahexaenoic acids) represented 19.7, 0.26, 0.26 and 7.64% of all fatty acids in plasma, respectively. This may reflect an adequate n-3 PUFA intake. LA was negatively (β = − 0.21, P = 0.004) but MA positively (β = 0.25, P < 0.001) associated with interleukin (IL)-6 in multivariate analyses. Neither ALA nor LC n-3 were independently associated with IL-6. During follow-up, 61 deaths and 115 kidney transplants occurred. Fully adjusted competing risk models showed that every percent increase in the proportion of plasma LA was associated with 12% reduction in mortality risk before transplantation (hazard ratio 0.88, 95% confidence interval 0.79-0.99). MA was directly associated with mortality. Neither ALA nor LC n-3 predicted outcome. Conclusions. The proportion of plasma phospholipid LA is inversely associated with IL-6 and all-cause mortality in Swedish dialysis patients. We raise the hypothesis that dialysis patients could benefit from increased intake of vegetable oils, the primary source of LA in the Western-type diet.
Introduction
Chronic kidney disease (CKD) patients, especially those progressing to end-stage renal disease (ESRD), are at increased cardiovascular morbidity and mortality risk [1] [2] [3] . Apart from traditional risk factors, persistent inflammation and malnutrition seem to play a major contributing role in this excess cardiac risk [4, 5] . Reduced nutrient intake due to spontaneous anorexia, dietary restrictions and nutrient losses into the dialysate not only strongly contribute to inflammation and malnutrition but are also associated with cardiovascular morbidity, mortality and adverse risk profile in this patient population [6, 7] .
Nutrients have diverse and important biological effects, particularly dietary fat [8] [9] [10] . However, whether specific nutrient intakes contribute to the risk profile in ESRD patients has not been well studied. Essential polyunsaturated fatty acids (PUFA), comprising both n-6 (omega-6) and n-3 (omega-3), exert a broad range of effects on the cardiac system including modulation of the inflammatory response [11, 12] . Essential PUFA include linoleic acid (LA; 18:2 n-6) and α-linolenic acid (ALA; 18:3 n-3) both present in vegetable oils as well as long-chain n-3 PUFA [LC n-3; including eicosapentaenoic acid (EPA; 20:5 n-3), docosapentaenoic acid (DPA; 22:5 n-3) and docosahexaenoic acid (DHA; 22:6 n-3)] present in fish, seaweed or algae [11, 12] . Reports using dietary food records show that American ESRD patients consume more saturated fat [13] and less LC n-3 than the current American Heart Association recommendations [14] ; however, this method is prone to under-reporting [15] . The use of plasma fat concentrations, on the other hand, is an objective and accurate method to estimate long-term fatty acid intake [16] . Understanding the associations between PUFA and risk profile in CKD patients is important, as it can be therapeutically targeted through nutritional interventions, but only a few small sample size studies have been performed [14, 17, 18] . Circulating levels of essential n-6 and n-3 PUFA may be particularly reliable biomarkers of essential fatty acid intake. The implications of circulating essential PUFA, as a reflection of long-term dietary intake, on the inflammatory risk profile and clinical outcome of ESRD subjects are still unclear [19] . We therefore investigated this by measuring plasma phospholipid n-6 and n-3 PUFA with gas-liquid chromatography in a carefully phenotyped cohort of dialysis patients.
Materials and methods

Subjects and study design
The ethics committee of Karolinska Institutet approved the study protocol, and informed consent was obtained from each individual. This is a post-hoc cross-sectional analysis with prospective follow-up where fatty acid profile was measured from frozen samples as part of an ongoing cohort study of incident dialysis patients described elsewhere [20] . Incident dialysis patients included in this cohort were invited to perform a second clinical assessment after ∼1 year of dialysis therapy. Patient recruitment occurred between April 1996 and October 2010. Exclusion criteria included age < 18 or >75 years, signs of overt infection and unwillingness to participate. From 434 patients included in the cohort, 255 attended the second visit. Reasons for not attending the second assessment included death (n = 45), kidney transplantation (n = 58) and unwillingness or unable to participate (n = 76). From these 255 patients, we excluded 6 patients with dialysis vintage < 4 or >18 months and 26 additional patients without sufficient plasma for fatty acid analysis. No differences were observed in general and demographic characteristics between the included 223 patients and non-included patients (data not shown). After fatty acid analysis was performed, one patient was excluded due to inconsistent chromatographic results. The study therefore comprises 222 (135 men, 61%) patients with a median age of 57 (10th-90th percentiles 37-69) years. One hundred and fourteen (51%) of patients underwent peritoneal dialysis, with a median dialysis time of 11.8 (8.4-13.5) months. The remaining 108 (49%) were on haemodialysis (HD) with a median dialysis time of 12.3 (10.5-13.7) months. Diabetes mellitus was present in 61 (28%) patients, while history of cardiovascular disease (CVD; defined as cardiac, cerebrovascular or peripheral vascular disease) was present in 75 (34%) patients. One hundred and three (53%) patients were current or past smokers and 93 (47%) patients were non-smokers. All patients were prospectively followed up for up to 5 years or until 30 April 2011, death or kidney transplantation, whichever event occurred first. Causes of death were extracted from medical records by a physician blind to the study results. Death due to CVD included fatal myocardial ischaemia or infarction, cardiac arrest or unknown sudden death, acute as well as chronic heart failure, cerebrovascular accidents, cerebral haemorrhage and ruptured aortic aneurysm.
Laboratory analyses
After an overnight fast, blood samples were obtained. Plasma and serum were separated and kept frozen at − 70°C, if not analysed immediately. Triglyceride, total cholesterol, high-density lipoprotein (HDL), high-sensitivity C-reactive protein (CRP) and albumin concentrations were analysed using certified methods in the Department of Laboratory Medicine at Karolinska University Hospital. The Friedewald equation [21] was used to calculate low-density lipoprotein (LDL) from total cholesterol, HDL and triglyceride. Serum concentrations of interleukin-6 (IL-6) were quantified by immunometric assays on an Immulite Analyzer (Siemens Medical Solutions Diagnostics, Los Angeles, CA).
Nutritional status
Subjective global assessment (SGA) was used to evaluate the overall nutritional status with a score of 1 indicating normal nutritional status. Protein-energy wasting (PEW) was defined as SGA >1 [22] . Handgrip strength was measured in the dominant hand (or non-fistula arm) with a Harpenden Handgrip Dynamometer (Yamar, Jackson, MI). The highest of three measurements was recorded. Body mass index (BMI) was calculated by the body weight divided by the square of the body height (kg/m 2 ).
Plasma phospholipid fatty acid composition
Plasma phospholipid fatty acid composition was analysed by gas-liquid chromatography at the Unit for Clinical Nutrition Research, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden. After separation of lipids by thin layer chromatography and trans-methylation, all fatty acids ranging from myristic acid (14:0) to DHA (22:6) were recorded and expressed as relative percentages (mol%) of total, as previously described in detail [23] . The coefficient of variation (CV) of this method was 1-5.5% in our laboratory, except for ALA, with a CV of 8.2% [24] .
This study analyses the relative proportions of essential PUFA [LA (n-6), ALA (n-3) and LC n-3 (representing the sum of EPA, DPA and DHA)] in the plasma phospholipids of dialysis patients as an indication of dietary intake [25, 26] . In support of this, Friedman et al. [14] reported a good agreement between plasma and erythrocyte n-3 PUFA levels with patient-reported fish intake in HD patients. In addition, we studied Mead acid (MA; 20:3 n-9), whose elevation in the blood is regarded as an indication of LA deficiency [27] . A disadvantage of this methodology is, however, that it cannot provide information on absolute intake of fatty acids or on total fat intake.
Statistical analyses
After assessing distribution with the Kolmogorov-Smirnov test, values were expressed as mean ± SD or median (10th and 90th percentiles) or percentage of total. Differences of PUFA studied between dialysis therapies were assessed after correction for age and sex using a mixed model procedure. Spearman's rank correlation analysis was used to determine relationships between LA, MA, ALA and LC n-3 with various variables. Multivariate regression models were fitted to assess independent relationships between PUFA and inflammatory markers. Data are expressed as adjusted coefficients of determination (R 2 ) and standardized regression coefficients (β). Classical Cox regression models were used for mortality analyses. As a sensitivity analysis, a shrinkage factor with Firth correction was applied to exclude the possibility of overfitting (monotone likelihood) [28, 29] . Because kidney transplantation and death before transplantation are mutually exclusive events (i.e. the occurrence of either one prevents the occurrence of the other), traditional Cox regressions may be biased; we therefore calculated the cumulative incidence of death before kidney transplant using the competing risk approach [30] . The adjustment for covariates used two approaches: firstly, adjustment for potential confounders (age, sex, comorbidities, dialysis modality and PEW); secondly, adjustment within the causal pathway in search of mechanism of action (IL-6 concentrations). Data are presented as hazard ratios (HR) and 95% confidence intervals (CI). All statistical analyses were performed using statistical software STATA version 12 (Stata Corporation, College Station, TX) and SAS version 9.2 (SAS Campus Drive, Cary, NC). Statistical significance was set at P < 0.05. Because P-values were not adjusted for multiple testing, they have to be considered as descriptive.
Results
General characteristics
The relative proportions of individual and LC n-3 PUFA present in plasma phospholipids are presented in Table 1 . Overall, the n-6 series, specifically LA, was the most abundant. In the case of LC n-3, DHA accounted for the majority of fatty acids. In agreement with previous reports [31] , the fatty acids studied did not differ between modalities (data not shown). Baseline clinical characteristics of the 222 dialysis patients included in the study are summarized in Table 2 .
Univariate and multivariate correlations
Using Spearman's univariate correlations (Table 2) , LA levels were negatively correlated with age, triglycerides, BMI, CRP and IL-6 ( Figure 1A ) and positively correlated with LDL, PEW and albumin. Opposite correlations were observed for MA ( Figure 1B) . ALA levels did not significantly correlate with CRP or IL-6. LC n-3 were negatively associated with PEW and CRP and positively associated with BMI and handgrip strength.
To test whether the associations between PUFA and inflammatory markers were independent of confounders, we used multivariate regression analyses shown in Table 3 . In these models, IL-6 negatively and positively contributed to explain LA and MA variances, respectively. Similar independent associations were observed for albumin (in opposite direction), but not for CRP (data not shown). IL-6 concentration did not associate with ALA and LC n-3 in multivariate models.
Mortality analyses
Sixty-one (27%) patients died during a median follow-up period of 18.4 (2.3, 60) months. The main causes of death were CVD-related (n = 37, 61% of total deaths). One hundred and sixteen (52%) individuals underwent kidney transplantation. Conventional Cox analyses showed that LA was associated with reduced risk of all-cause mortality [ per 1% increase, adjusted HR (95% CI), 0.89 (0.81-0.99), same covariates as in Table 4 ], while MA associated with increased mortality risk [ per 0.1% increase, 1.30 (1.08-1.57)]. No significant associations between ALA, LC n-3 and mortality were observed. Results were confirmed as a sensitivity analysis after applying a shrinkage factor with Firth correction (data not shown).
Cox regression models for competing risks are shown in Table 4 . In the crude models, each percentage of increase in the proportion of LA reduced the mortality risk before kidney transplantation by 11% [HR (95% CI), 0.89 (0.81-0.98)], a magnitude little affected by adjustment of confounders (Model 1). MA was directly associated with mortality, in both crude and adjusted analyses. Although a trend towards reduced mortality was observed for increasing proportion of ALA and LC n-3, the hazards did not reach statistical significance nor did the hazards for EPA or DHA alone (data not shown). In all these models, adjusting within the causal pathway (Model 2 plus IL-6 concentrations) did not modify the results.
Discussion
The present study investigates possible links between circulating essential PUFA, systemic inflammation and the a Data are expressed as mean ± SD, median (10th and 90th percentiles) or number of subjects (percentages), as appropriate. Spearman's rank correlation analysis was used to determine correlations of PUFA with other variables. BMI, body mass index; LC n-3, long-chain n-3 PUFAs (the sum of eicosapentaenoic, docosapentaenoic, and docosahexaenoic acids). Bold values mark those associations that are statistically significant. *P < 0.05. **P < 0.01. 0.09 ± 0.04 20:3 n-6
2.76 ± 0.71 20:4 n-6
9.18 ± 1.59 18:3 n-3 0.26 ± 0.09 20:5 n-3
1.60 ± 0.73 22:5 n-3
1.16 ± 0.21 22:6 n-3
4.88 ± 1.13 20:3 n-9 0.26 ± 0.12 LC n-3
7.64 ± 1.71 a Data are presented as mean ± SD. 18:2 n-6, LA; 18:3 n-6, γ-linolenic acid; 20:3 n-6, dihomo-γ-linolenic acid; 20:4 n-6, arachidonic acid; 18:3 n-3, ALA; 20:5 n-3, eicosapentaenoic acid; 22:5 n-3, docosapentaenoic acid; 22:6 n-3, docosahexaenoic acid; 20:3 n-9, MA; LC n-3, long-chain n-3 PUFAs (the sum of eicosapentaenoic, docosapentaenoic and docosahexaenoic acids).
mortality risk of dialysis patients. To our knowledge, this is the first report of this type. An important and novel finding for CKD patients is the observation that circulating LA, the major dietary n-6 PUFA present in vegetable oils, correlates to reduced IL-6 concentrations. This agrees with previous community reports [32] [33] [34] and altogether adds to the growing evidence in the general population that an increase in circulating LA associates with reduced inflammation, reduced cardiovascular risk as well as improved outcomes [35] [36] [37] [38] . We importantly observed an inverse association between circulating LA levels and the risk of all-cause mortality, which held true even after considering inflammation ( purportedly within the causal pathway). Noninflammatory mechanisms by which LA may be linked to reduced mortality could include improvement in insulin sensitivity and reduced risk of type 2 diabetes [39, 40] as well as lowering of cholesterol [39] and systolic blood pressure [41] . Our observations for MA may further reinforce this observation, as under conditions of LA insufficiency, oleic acid (18:1 n-9) can be endogenously elongated and desaturated to synthesize MA, which has pro-inflammatory effects [27, 42] . Thus, the positive association between MA and inflammation as well as the direct prediction of MA on patient mortality is an indirect reinforcement of the consequences of LA deficiency.
We did not observe an association between circulating n-3 PUFA and inflammation. However, this is in agreement with findings in Swedish community studies [32, 33] and with a previous American report in dialysis patients using n-3 PUFA intake estimated from dietary records [43] . The absent relationship between n-3 PUFA and inflammation in our study could be explained by the stronger links that n-3 PUFA shared with PEW. Nevertheless, our results do not contradict the notion that supplementation with n-3 PUFA has the potential to reduce systemic inflammation in CKD patients [44, 45] . It has Because of small proportions, the levels of MA and ALA were multiplied by 10 to show meaningful risks estimates, thus depicting the risk associated with 0.1% increase; Model 1 is adjusted for sex, age, comorbidities (composite score of diabetes mellitus and CVD), dialysis modality and PEW (by SGA); Model 2 is adjusted for factors detailed in Model 1 plus IL-6. No interactions (the PUFAs × sex, the PUFAs × dialysis modality and the PUFAs × PEW) were observed. LC n-3, long-chain n-3 PUFAs (the sum of eicosapentaenoic, docosapentaenoic and docosahexaenoic acids). been reported that dialysis patients have reduced plasma n-3 PUFA levels [14, 46] and thereby, circulating levels may not suffice to exert their anti-inflammatory effects.
The proportion of n-3 PUFA in our study is consistent with that reported for the general Swedish population and purportedly reflects and adequate fish intake [47] . Interestingly, n-3 PUFA was not associated with mortality, a result which, however, agrees with findings from the general Swedish population where n-3 PUFA intake is high [38] but also with previous evidence in dialysis patients using either erythrocyte n-3 PUFA content [17] or dietary-estimated n-3 PUFA [43] . Kutner et al. [48] reported that higher fish intake is associated with decreased mortality risk in incident dialysis subjects. Divergences in results may be attributed to methodological issues (food frequency questionnaires versus plasma PUFA content) as well as study design. Also, Hamazaki et al. [18] showed that Japanese dialysis patients within the highest tertile of erythrocyte DHA content had a reduced mortality risk. Again, variances in the source of n-3 PUFA content between that and our study (erythrocyte versus plasma phospholipids), the use of categories in studies with reduced sample size and especially the likely differences in fish intake between Swedish and Japanese populations, limit comparison. While further research is needed to confirm our results, regional, cultural and individual dietary differences may preclude a general conclusion regarding the association between PUFA and risk profile. Thus, our findings should be contemplated within the context of Western-type and Swedish diet. Despite the present study is the largest of its kind in dialysis patients, it should be noted that the magnitude of the reduced risk estimates was in fact similar between n-6 and n-3 PUFA.
Our results should be interpreted considering the study's strengths and limitations. Our observational design cannot infer causality in these associations. Having patients with similar dialysis durations eliminates an important confounder, but it also conveys a selection of individuals that limits the ability to generalize to other populations. The use of continuous variables (reducing residual confounding) and competing risk models strengthens our results. Detailed phenotypic characterization allows us to take into account potential confounders of the complex phenotype of uraemic patients, although unmeasured or unknown ones are likely to be present. Our analysis has the strength of focussing on essential PUFA, which reduces the impact of multiple comparisons and addresses the biological value of specific fatty acids, functionalities and food sources [49] . However, circulating PUFA may also represent the intake of certain foods that can contain other beneficial nutrients that may contribute to the observed effects. Although studies in the general population show in general a good agreement between dietary fat and circulating fatty acids [25, 26] , there is no data validating this statement in CKD patients. Thus, the lack of dietary intake data to corroborate the dietary biomarkers is acknowledged as a final limitation in the interpretation of our findings.
To conclude, in a relatively large cohort of dialysis patients, plasma LA, an indicator of vegetable oil intake, was independently and inversely related to systemic inflammation and all-cause mortality risk. No significant association was observed for n-3 PUFA in this dialysis population with adequate fish intake. Whereas most studies to date have been designed to investigate the effects of n-3 PUFA [44, 45] , our data suggest that more research focus should be given to the potential benefits of n-6 PUFA from vegetable oils. Data on effects of n-6 PUFA supplementation in dialysis patients are almost non-existent, with only Begum et al. [50] demonstrating a trend towards a decrease in leukotriene B 4 (a pro-inflammatory eicosanoid) production. Our results raise the hypothesis that dialysis patients could benefit from increased intake of vegetable oils, the primary source of LA in the Western-type diet. Such strategies are being successfully tested in non-CKD individuals and previous controlled trials suggest cardiovascular benefits when substituting saturated fatty acids in the diet specifically for LA-rich PUFA [8, 39, 51] , effects mostly mediated by anti-hyperlipidaemic mechanisms [8, 39, 51] but perhaps also by a reduction in plasma concentrations of inflammatory markers as shown in obese subjects after sunflower oil (LA-rich) supplementation [52] .
